An open-label pilot study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine

Journal of Headache and Pain

Volumn 4, Issue 2, 2003, Pages 92-96

  Gallai, Virgilio ^a   Alberti, Andrea ^a   Rossi, Cristiana ^a   Coppola, Francesca ^a   Gallai, Beatrice ^a   Mazzotta, Giovanni ^a   Sarchielli, Paola ^a  

^a Neurologic Clinic   (Italy)

Author keywords

Levetiracetam; Migraine without aura; Open label study; Prophylaxis

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; PYRROLIDINE DERIVATIVE;

ADULT; ARTICLE; ASTHENIA; BALANCE DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MIGRAINE; PILOT STUDY; PRIORITY JOURNAL; SOMNOLENCE; STATISTICAL ANALYSIS;

EID: 0042856459     PISSN: 11292369     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10194-003-0043-8     Document Type: Article

References (15)

1. Roba J (1998) Preclinical expert report on levetiracetam (Keppra). Report: RXLE 98L 3002. December 1998 submitted to EMEA
2. Sander JW, Mitchell TN (2001) Levetiracetam: a new antiepileptic drug for the adjunctive therapy of chronic epilepsy. Drugs Today (Barc) 37:665-673
3. Bazil CW (2002) New antiepileptic drugs. Neurolog 8:71-81
4. Stratton SC, Large CH, Cox B, Davies G, Hagan RM (2003) Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model. Epilepsy Res 53:95-106
5. Noyer M, Gillard M, Matagne A, Henichart JP, Wulfert E (1995) The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 286:137-146
6. Lukyanetz EA, Shkryl VM, Kostyuk PG (2002) Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43:9-18
7. Browne TR, Szabo GK, Leppik IE, Josephs E, Paz J, Baltes E, Jensen CM (2000) Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J Clin Pharmacol 40:590-595
8. Crawford P (2002) Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 16:263-272
9. Patsalos PN (2003) The pharmacokinetic characteristics of levetiracetam. Methods Find Exp Clin Pharmacol 25:123-129
10. Haria M, Balfour JA (1997) Levetiracetam. CNS Drugs 7:159-164
11. Haria M, Balfour JA (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 8[Suppl 7]:1-96
12. Krusz JC (2001) Levetiracetam as prophylaxis for resistant headaches. Cephalalgia 21:373 (abstract)
13. Drake ME, Greathouse NI, Armentbright AD, Renner JB (2001) Levetiracetam for preventive treatment of migraine. Cephalalgia 21:373 (abstract)
14. Rothrock JF, Mendizabal JE (2000) An analysis of the "carry-over effect" following successful short-term treatment of transformed migraine with divalproex sodium. Headache 40:17-19
15. Palmer JE, Chronicle EP, Rolan P, Mulleners WM (2000) Cortical hyper-excitability is cortical under-inhibition: evidence from a novel functional test of migraine patients. Cephalalgia 20:525-532